UK markets close in 7 hours 23 minutes

Fulgent Genetics, Inc. (FLGT)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
74.59+0.64 (+0.87%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close73.95
Open74.28
Bid0.00 x 1000
Ask0.00 x 800
Day's range73.80 - 75.56
52-week range15.30 - 189.89
Volume639,995
Avg. volume1,117,947
Market cap2.163B
Beta (5Y monthly)1.51
PE ratio (TTM)4.72
EPS (TTM)15.82
Earnings date02 Aug 2021 - 06 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est87.00
  • 2 Stocks That Are More Likely to Double Your Money Than Dogecoin
    Motley Fool

    2 Stocks That Are More Likely to Double Your Money Than Dogecoin

    Teladoc (NYSE: TDOC) and Fulgent Genetics (NASDAQ: FLGT) are significantly off their highs but have booming businesses that will eventually catch up with their stock prices. Overall growth was 151%, with 69% attributable to the legacy business -- without acquisitions. The stock is nearly 50% off its all-time high as investors fret over slowing member growth and concerns that the need for virtual visits will collapse as cases of COVID-19 disappear.

  • What Does Life After COVID Look Like for Fulgent Genetics?
    Motley Fool

    What Does Life After COVID Look Like for Fulgent Genetics?

    Legendary investor Benjamin Graham, a mentor of Warren Buffett, is thought to have originated the idea of "special situation" investments. In his classic book the Intelligent Investor, Graham discussed how there can be mispricing between assets and markets. Fulgent Genetics (NASDAQ: FLGT) may have found itself in a very special situation where the market is mispricing the core assets of the company due to the cloud of uncertainty surrounding COVID testing.

  • Motley Fool

    How Long Will Fulgent Genetics Benefit From the Pandemic?

    In this video from Motley Fool Live, recorded on May 10, Fool.com contributors Brian Orelli and Keith Speights discuss how long that benefit could last and how investors should value the company accordingly. Brian Orelli: The number of COVID-19 tests performed in the U.S. has been dropping precipitously. Speights: No. That's what Fulgent did in Q1.